Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Web Exclusives

Web Exclusives published on March 2, 2021 in Breast Cancer, FDA Updates
On December 16, 2020, the FDA approved margetuximab-cmkb (Margenza), in combination with chemotherapy, for the treatment of adults with metastatic HER2-positive breast cancer. “As the only HER2-targeted agent to have shown a PFS improvement versus trastuzumab in a head-to-head phase 3 clinical trial, Margenza with chemotherapy represents the newest treatment option for patients who have progressed on available HER2-directed therapies,” said Hope S. Rugo, MD.
Web Exclusives published on March 2, 2021 in FDA Updates, Prostate Cancer
On December 18, 2020, the FDA approved relugolix (Orgovyx), an oral GnRH receptor antagonist, for the treatment of men with advanced prostate cancer. This “approval marks the first oral drug in this class, and it may eliminate some patients’ need to visit the clinic for treatments that require administration by a health care provider. This potential to reduce clinic visits can be especially beneficial in helping patients with cancer stay home and avoid exposure during the coronavirus pandemic,” said Richard Pazdur, MD.
Web Exclusives published on February 18, 2021 in Cholangiocarcinoma
Targeted therapy has improved survival for patients with cancer across a broad spectrum of disease sites, but until recently, progress has been slow in the treatment of patients with cholangiocarcinoma (CCA).
Web Exclusives published on February 18, 2021 in Cholangiocarcinoma
Early studies with NUC-1031 alone or in combination with cisplatin showed higher-than-expected responses in patients, supporting that this mechanism is working, with no new or worsening side effects compared with gemcitabine.
Web Exclusives published on February 18, 2021 in Cholangiocarcinoma
In April 2020, the FDA granted accelerated approval to pemigatinib (Pemazyre), the first targeted therapy for cholangiocarcinoma (CCA). The FGFR inhibitor was approved for adults with CCA and FGFR2 fusion.
Web Exclusives published on February 18, 2021 in Cholangiocarcinoma
The recent FDA approval of the first FGFR inhibitor, pemigatinib (Pemazyre), and the positive results from the phase 3 study of the first IDH1 inhibitor, ivosidenib (Tibsovo), represent major breakthroughs in the treatment of patients with cholangiocarcinoma (CCA), a rare cancer associated with poor outcomes. However, the duration of response with these agents is still relatively short.
Web Exclusives published on February 18, 2021 in Cholangiocarcinoma
Patient-derived tumor organoids may have clinical application to predict drug responses in a personalized treatment setting; they have shown concordance with actionable genomic anchors and retrospective treatment outcomes.
Web Exclusives published on February 18, 2021 in Cholangiocarcinoma
New cytotoxic chemotherapy regimens and novel combinations are being evaluated in clinical trials in an effort to improve the outcomes of chemotherapy in the adjuvant and palliative settings in patients with biliary tract cancer, including cholangiocarcinoma (CCA), said Angela Lamarca, MD, PhD, MSc, Consultant, Medical Oncology, the Christie NHS Foundation Trust, Manchester, United Kingdom. She discussed the future of cytotoxic chemotherapy for this patient population at the 2020 Cholangiocarcinoma Summit.
Web Exclusives published on January 12, 2021 in Ovarian Cancer
Patient-reported outcomes from the phase 3 PRIMA clinical trial showed no detrimental effect of niraparib on quality-of-life measures compared with placebo in patients with newly diagnosed ovarian cancer.
Web Exclusives published on January 12, 2021 in Ovarian Cancer
Information on clinical aspects of COVID-19 and social and financial support services for the cancer community are abundant.
Page 1 of 30
Results 1 - 10 of 300